<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6940</article-id>
      <article-id pub-id-type="doi">10.51847/5QN65SjElH</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synthesis Begins at Generation: Embedding Route Feasibility, Material Availability, and Process Burden into Molecular Design</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>Roberts</surname>
                <given-names>Michael</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Thompson</surname>
                <given-names>Sarah</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Anderson</surname>
                <given-names>James</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Smith</surname>
                <given-names>Robert</given-names>
              </name>
                              <xref rid="aff4" ref-type="aff">4</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of Synthesis-Aware Molecular Generation, Faculty of Pharmacy, University of Glasgow, Glasgow, United Kingdom.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Route Feasibility and Material Availability, Faculty of Pharmacy, University of Auckland, Auckland, New Zealand.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Process Burden and Manufacturability, Faculty of Pharmacy, University of Manchester, Manchester, United Kingdom.
          </aff>
                  <aff id="aff4">
            <label>4</label>Department of Synthesis-Embedded Molecular Design, Faculty of Pharmacy, University of Edinburgh, Edinburgh, United Kingdom.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                              E-mail: <email xlink:href="michael.roberts@glasgow.ac.uk">michael.roberts@glasgow.ac.uk</email>
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>28</day>
        <month>12</month>
        <year>2025</year>
      </pub-date>
      <volume>16</volume>
      <issue>6</issue>
      <fpage>56</fpage>
      <lpage>65</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Generative molecular design can propose chemically valid structures with attractive predicted properties, yet many candidates remain disconnected from a credible path to synthesis. Treating synthesizability as a post hoc filter creates a structural inefficiency: molecular objectives are optimized before route feasibility, precursor availability, operational burden, and planning uncertainty are allowed to influence the design itself. This article develops an original synthesis-constrained design theory in which synthesis begins during molecular generation rather than after it. The proposed construct, termed Route-Embedded Design Viability, represents each candidate as a coupled molecule–route hypothesis characterized by molecular value, step-level reaction feasibility, route topology, context-specific material availability, anticipated process burden, and an explicit uncertainty envelope. The theory distinguishes molecular plausibility from route viability, predicted reaction feasibility from experimental confirmation, catalogue presence from usable material access, and early process indicators from validated manufacturing evidence. It further proposes that molecular value and route viability should be optimized jointly through constrained or Pareto-based search rather than collapsed automatically into a single score. Evaluation should therefore progress from structural integrity and predictive relevance to full retrosynthetic search, route comparison, material verification, process-burden assessment, uncertainty analysis, and expert review of an executable synthesis plan. The contribution is conceptual and methodological rather than empirically validated. Its applicability remains conditional on reaction-data quality, planner configuration, stock definitions, process assumptions, project objectives, and human expertise. By repositioning synthesis evidence as a generative input, the theory provides a bounded basis for designing molecules whose predicted pharmaceutical value is considered together with the practical consequences of making them.</p>
      </abstract>
      <kwd-group>
                <kwd>Generative molecular design</kwd>
                <kwd>Retrosynthesis</kwd>
                <kwd>Synthetic accessibility</kwd>
                <kwd>Route feasibility</kwd>
                <kwd>Material availability</kwd>
                <kwd>Process burden</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>